China Life's venture capital arm, China Life Private Equity, focuses on being a long-term value investor in sectors such as life science, med-tech, healthcare services, and digital health. More broadly, China Life aims to invest in growth-stage enterprises and strategic emerging industries, including AI, aligning its strategy with national development priorities and increasing its allocation to equity investments within Chinese domestic markets.
Their most common stage is growth (50% of deals). Average disclosed round size is $3629.7M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Growth
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 XtalPi Inc. | Series C | $318.8M | Sep 2020 |
 JD Logistics | Growth | $2.5B | Feb 2018 |
 Didi Chuxing | Growth | $7.2B | Jun 2016 |
 Ant Financial | Series B | $4.5B | Apr 2016 |
Top Co-Investors
Tencent Investment2 shared
Sequoia China2 shared
Hillhouse Capital1 shared
China Merchants Group1 shared
SoftBank Vision Fund1 shared
Morningside Ventures1 shared
SIG1 shared
BlackRock1 shared
Apple1 shared
China Growth Capital1 shared
CCB Trust1 shared
Primavera Capital1 shared
Last updated: 16 April 2026